Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

‘Transformational’ new breast cancer drug could halt the growth of tumours

A trial funded by AstraZeneca found the drug is effective in stopping cancer cells from using hormones to grow

The Independent UK

Short Sellers Are Taking Aim at Buy-Rated Tempus AI. Should You Buy TEM Stock Here?

Tempus AI stock fell over 19% after Spruce Point Capital released a short report. Can TEM stock recover?

Barchart

How the love story between von der Leyen and Pfizer turned sour

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

The Guardian - UK

Tempus AI Stock: Time to Double Down or Cut and Run?

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

MarketBeat

AstraZeneca Moves Some Production To US Amid Tariff Threat

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.

International Business Times

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca plots US expansion despite Trump tariff threat

The drug maker said it is ‘firmly committed to investing and growing in the US’ amid potential import tariffs on the pharmaceutical industry.

Evening Standard

Trade war with China to hit US healthcare

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Al Jazeera

Drug firm bosses call for price increases in Europe amid tariff uncertainty

The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.

Evening Standard

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

MarketBeat

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?

TRUMP TARIFFS: UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports

The Independent UK

Ministers in ‘active conversation’ with UK drug firms over potential tariffs

Government seeks ways to shield industry from possible US levies amid concern over effect on medicine supply

The Guardian - UK

Scramble underway to stop Trump tariffs hitting Britain’s pharmaceutical industry

Donald Trump has warned tariffs on pharmaceuticals would come ‘in the not-too-distant future’

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

UK scrambling to get Donald Trump to slash tariffs to zero, says minister as US threatens medicines levies

Tariffs on Britain’s pharmaceutical industry could deal a severe blow, potentially costing firms billions of pounds

The Independent UK

‘Game-changing’ breast cancer pill to be offered on NHS

The new treatment helps to slow or stop the spread of cancer cells

The Guardian - UK

‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales

U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year

The Independent UK

‘Landmark moment’ as new pill approved for common type of advanced breast cancer

The Institute of Cancer Research, London, which helped develop the drug, welcomed the move.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Uganda’s boda boda bikes are deadly polluters: study models how going electric could save lives

In Uganda, motorcycles known as boda bodas are a key part of the transport system. The country has over 1.5 million boda bodas on the road, amounting to roughly 70% of all vehicles. Boda bodas are crucial in providing last mile transport for people and goods on short trips because…

The Guardian - UK

China, America and pay inject drama into AstraZeneca’s AGM

The boss’s bonus is an annual debating point at Britain’s biggest company. But that’s not the only issue this year

Evening Standard

Trump tariffs: Which UK sectors will be hit hardest?

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

The Conversation

How Beijing plans to bounce back against Trump’s tariffs

China’s president Xi Jinping recently held a meeting with 40 leaders of multinational companies, including BMW and AstraZeneca.

The Guardian - UK

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Pharma company will invest money over five years in ‘strategic partnership’ after ditching UK expansion

The Guardian - UK

AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’

UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug

Fortune

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.